Proteocyte AI

Can AI help remove subjectivity from oral dysplasia assessment?

As a guest on the Everyday Oral Surgery podcast, Dr. Paras Patel, DDS, discussed the role of AI, as used in the STRATICYTE® test.

A big challenge in pathology is variability. The same lesion may be graded differently by different clinicians—or even by the same clinician on a different day.

That’s where AI has the potential to make an impact.

The goal isn't to replace clinical expertise—it's to enhance it with data-driven insights that help predict which lesions are most likely to transform.

At the end of the day, improving objectivity means improving confidence in clinical decision-making.

Learn more about STRATICYTE® : 👉 https://proteocyte.com/straticyte/


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

ICYMI Dr. Paras Patel, DDS, was a guest on the podcast Everyday Oral Surgery, this spring.

Here he discusses traditional and nontraditional risk factors for oral lesions.

When we think about oral cancer risk, to***co and alcohol are still major contributors—but they're no longer the whole story.

More clinicians are seeing patients with oral dysplasia and oral cancer who don't fit the traditional risk profile. HPV, chronic iron deficiency, diabetes, immune dysfunction, and other systemic health factors may all play a role, yet many questions remain unanswered.

As oral pathology continues to evolve, the focus is shifting from treating disease to identifying risk earlier.

Learn more about how STRATICYTE® can make a difference—helping predict oral cancer risk and supporting earlier, more informed patient management: 👉 https://proteocyte.com/straticyte/

Listen to the full podcast: 🎧 https://www.buzzsprout.com/1404670/episodes/18784235


Alberta Dental Association Association des chirurgiens dentistes du Québec - ACDQ BC Cancer Foundation BC Dental Association CancerCare Manitoba Canadian Association of Oral and Maxillofacial Surgeons Canadian Cancer Society

This spring, Dr. Paras Patel, DDS, was a guest on the podcast Everyday Oral Surgery.

Here he discusses his relationship with Proteocyte and how the STRATICYTE® test applies S100A7 biomarker analysis combined with AI-driven cytomorphometric evaluation to help clinicians better predict which oral lesions may transform over time.

What makes this especially powerful?
✔️ Personalized risk assessment
✔️ Built on 15+ years of clinical data
✔️ No additional biopsy required

The shift toward precision diagnostics is making earlier, more informed intervention possible in oral pathology and cancer prevention.

Learn more about STRATICYTE® : 👉 https://proteocyte.com/straticyte/

Listen to the full podcast: 🎧 https://www.buzzsprout.com/1404670/episodes/18784235


American Academy of Otolaryngology—Head and Neck Surgery American Academy of Oral Medicine American Academy of Oral and Maxillofacial Pathology - AAOMP American Association of Oral and Maxillofacial Surgeons - AAOMS American Cancer Society

The tide is shifting in oral cancer care.

From reactive monitoring → to a more proactive approach to managing oral lesions.

“Oral SCC is not like other cancers.”
Progression isn’t always predictable—and waiting for visible change can delay intervention.

So where should we be going?

Toward earlier, more precise risk identification.

STRATICYTE® supports this shift by providing an objective, personalized risk assessment, helping clinicians better understand which lesions may progress—and act sooner.

Watch the full webinar:
👉 https://vimeo.com/1166776243/70fe5d4b60


Nova Scotia Dental Association Ontario Dental Association Ontario Society of Oral and Maxillofacial Surgery The Terry Fox Foundation The Princess Margaret Cancer Foundation

This spring, Dr. Paras Patel, DDS, was a guest on the podcast Everyday Oral Surgery.

Here he discusses how oral cancer rates have continued to rise over the last two decades, and how it’s changing the conversation around oral lesion management.

There’s is no true standard approach for managing mild dysplasia or leukoplakia. Some clinicians monitor yearly, some take a more aggressive route, and others may not intervene at all.

But with increasing cancer diagnoses and current WHO dysplasia grading criteria, the field is shifting toward earlier detection, closer monitoring, and more proactive intervention.

Learn more about how STRATICYTE® can make a difference—helping predict oral cancer risk and supporting earlier, more informed patient management: 👉 https://proteocyte.com/straticyte/

Listen to the full podcast: 🎧 https://www.buzzsprout.com/1404670/episodes/18784235


American Dental Association Beacon Oral & Maxillofacial Surgeons Everyday Oral Surgery Head and Neck Cancer Alliance Osteo Science Foundation Oral Cancer Foundation Paradigm Oral Health